Life Sciences weekly highlights—12 September 2024

Article summary

This week's edition of Life Sciences weekly highlights includes Law360 news of the Court of Appeal decision in the hydrocortisone tablet alleged price-fixing cartel investigation that overturned the Competition Appeal Tribunal’s decision and upheld £100m in fines against the group of pharmaceutical companies. An MLex news analysis provides commentary on the wider impact of last week’s Illumina/GRAIL victory on the EU’s system of merger control. Another major development this week is that Mario Draghi’s report on ‘The future of European competitiveness’ has been published, alongside an in-depth analysis with recommendations to enhance the EU's competitiveness including focus on incentives for life sciences R&D innovation, including an emphasis on AI, and regulatory reforms which the European pharmaceutical and medical devices industry bodies welcomed. Other important news includes that the EMA and the Heads of Medicines Agencies (HMA) have published guiding principles for using large language models (LLMs) across the European medicines regulatory network (EMRN) as part of the 2023–28 AI workplan, the MHRA released guidance on the implementation...